Stemedica - Investor Relations

INVESTOR RELATIONS

As a multiple product company within the stem cell industry, Stemedica has the ability to advance one product against several distinct medical conditions with a single strategic investment. This strategy allows Stemedica to provide our investors with a larger measure of confidence in our success and with multiple opportunities to monetize their investment.

Roger Howe, PhD
Executive Chairman

Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult stem cell products and biological compounds. Stemedica is a privately held corporation headquartered in San Diego, California, with international operations based out of Lausanne, Switzerland.

From an investment standpoint, the Company is uniquely positioned in a dynamic industry with multiple opportunities for monetization. The Company is currently completing its Preferred Series B Round of financing and is seeking qualified and accredited investors who identify with Stemedica’s vision. Series B financing is open on a limited time basis.

For investment information in Stemedica, contact Marcie Frank, Manager of Investor Relations, at 858-658-0910 Ext. 7205, or mfrank@stemedica.com.

Mailing address:
Investor Relations
Stemedica Cell Technologies, Inc.
5375 Mira Sorrento Place, Suite 100
San Diego, CA 92121
858-658-0910 x 7205